Results 121 to 130 of about 82,390 (337)

Novel ATR/PARP1 Dual Inhibitors Demonstrate Synergistic Antitumor Efficacy in Triple‐Negative Breast Cancer Models

open access: yesAdvanced Science, EarlyView.
Novel ATR/PARP1 dual inhibitors are developed for the first time. Advanced lead B8 effectively reduces cell viability in vitro and suppresses tumor growth in vivo, with better potency than ATRi and PARPi alone or in combination. Mechanistically, B8 induces apoptosis, arrests the cell cycle, and inhibits cancer cells colony formation, migration, and ...
Yuan Gao   +13 more
wiley   +1 more source

TRIM21‐Mediated K11‐Linked Ubiquitination of ID1 Suppresses Tumorigenesis and Promotes Cuproptosis in Esophageal Squamous Cell Carcinoma

open access: yesAdvanced Science, EarlyView.
ID1 is regulated by E3 ligase TRIM21, which adds non‐degradative K11‐linked ubiquitin at Lys91, disrupting ID1‐TCF12 binding and freeing TCF12 to upregulate copper transporter SLC31A1. Enhanced SLC31A1 elevates intracellular copper, triggers cuproptosis, and inhibits ESCC growth.
Lei Li   +6 more
wiley   +1 more source

Breast radiation-associated secondary malignancies: A review

open access: yesClinical Surgical Oncology, 2023
Secondary malignancies are a late complication of radiation treatment for primary cancer through DNA damage. Specifically after breast cancer radiation, a number of tissues are vulnerable to radiation damage and have increased risk for developing ...
Sarah Poland   +3 more
doaj  

Multiple primary malignant neoplasms in patients with esophageal cancer [PDF]

open access: bronze, 2008
S. Nagasawa   +4 more
openalex   +1 more source

HLA‐DR⁺ Tumor Cells Show an Association with a Distinct Immune Microenvironment and CD8⁺ T‐Cell Exhaustion in HBV‐Associated Hepatocellular Carcinoma

open access: yesAdvanced Science, EarlyView.
This study integrates scRNA‐seq, multiplex immunofluorescence, and clinical data to identify HLA‐DR⁺tumor cells uniquely enriched in Hepatocellular carcinoma (HCC) with hepatitis B virus (HBV). These cells express MHC II, associate with PD‐L1, recruit and exhaust CD8⁺T cells, predict poor survival, and serve as potential biomarkers for immunotherapy ...
Jun‐Qing Chang   +17 more
wiley   +1 more source

Fistula aorto-esofágica en un paciente con cáncer de esófago

open access: yesRevista Electrónica Dr. Zoilo E. Marinello Vidaurreta, 2016
La fistula aorto-esofágica es una complicación infrecuente del cáncer de esófago, pero extremadamente agresiva. Se presenta un paciente fumador, bebedor ocasional, que ingresa por disnea intensa, tos con expectoración, disfagia y síntomas generales que ...
Alfredo Enrique Arredondo Bruce   +2 more
doaj  

LIMK1 as a Novel Kinase of β‐Catenin Promotes Esophageal Cancer Metastasis by Cooperating With CDK5

open access: yesAdvanced Science, EarlyView.
Li et al. innovatively map the kinase‐substrate network in esophageal cancer metastasis. Their study demonstrates that LIM domain kinase 1 (LIMK1) and Cyclin‐dependent kinase 5 (CDK5) synergistically increase the phosphorylation of β‐catenin, thereby activating the Wnt/β‐catenin signaling pathway to promote esophageal cancer metastasis.
Shu‐Jun Li   +27 more
wiley   +1 more source

Molecular cytogenetic evaluation of gastric cardia adenocarcinoma and precursor lesions [PDF]

open access: yes, 2001
Analyses of cancer incidence data in the United States and Western Europe revealed steadily rising rates over the past decades of adenocarcinomas of the esophagus and gastric cardia.
Alers, J.C. (Janneke)   +5 more
core   +1 more source

NPR1 Promotes Lipid Droplet Lipolysis to Enhance Mitochondrial Oxidative Phosphorylation and Fuel Gastric Cancer Metastasis

open access: yesAdvanced Science, EarlyView.
NPR1 induces lipolysis of stored lipid droplet and enhances mitochondrial oxidative phosphorylation to fuel gastric cancer metastasis. Specifically, NPR1‐mediated activation of PKG directly phosphorylates and activates HSL at Ser855 and Ser951, thereby driving lipolytic processes.
Huafeng Fu   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy